Xavier Montalban


Scientist, Li Ka Shing Knowledge Institute

Research Programs


Dr. Xavier Montalban is an internationally recognized neurologist who is considered a key opinion leader within the field of multiple sclerosis (MS). Dr. Montalban has held diverse leadership positions and is currently a Professor of Medicine and Director of the Neurology Department at the University of Toronto. He also serves as Chair of the Department of Neurology-Neuroimmunology and Director of the Multiple Sclerosis Centre of Catalonia at the Vall d’Hebron University Hospital in Barcelona, Spain. The Multiple Sclerosis Centre of Catalonia, or Cemcat, is accredited as a national flagship service for the MS care process within the context of the Flagship Centres, Units, and Services programme of the Spanish Ministry of Health. Dr. Montalban is a former president of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and recently co-directed the development of the first Multiple Sclerosis Treatment Guidelines for ECTRIMS and the European Academy of Neurology. He has contributed more than 500 publications and several book chapters to the academic arena, served on multiple steering committees of clinical trials related to multiple sclerosis, and is a valued member of the International Panel on Multiple Sclerosis Diagnostic Criteria and Clinical Trials. With more than 25 years of research, Dr. Montalban continues to strive to discover more effective therapies for patients with MS and has brought paradigm shifts to the way we understand and treat MS.

Recent Publications

  1. Gold, R, Radue, EW, Giovannoni, G, Selmaj, K, Havrdova, EK, Montalban, X et al.. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J. Neurol. 2020; :. doi: 10.1007/s00415-020-09835-y. PubMed PMID:32451615 .
  2. Giovannoni, G, Galazka, A, Schick, R, Leist, T, Comi, G, Montalban, X et al.. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Saf. 2020; :. doi: 10.1007/s40264-020-00948-x. PubMed PMID:32447743 .
  3. Clarke, MA, Pareto, D, Pessini-Ferreira, L, Arrambide, G, Alberich, M, Crescenzo, F et al.. Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. AJNR Am J Neuroradiol. 2020; :. doi: 10.3174/ajnr.A6547. PubMed PMID:32439639 .
  4. Matute-Blanch, C, Calvo-Barreiro, L, Carballo-Carbajal, I, Gonzalo, R, Sanchez, A, Vila, M et al.. Chitinase 3-like 1 is neurotoxic in primary cultured neurons. Sci Rep. 2020;10 (1):7118. doi: 10.1038/s41598-020-64093-2. PubMed PMID:32346016 PubMed Central PMC7188887.
  5. Cortese, M, Munger, KL, Martínez-Lapiscina, EH, Barro, C, Edan, G, Freedman, MS et al.. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 2020;94 (18):e1950-e1960. doi: 10.1212/WNL.0000000000009371. PubMed PMID:32300060 .
  6. Derfuss, T, Sastre-Garriga, J, Montalban, X, Rodegher, M, Wuerfel, J, Gaetano, L et al.. The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. ;6 (1):2055217320907951. doi: 10.1177/2055217320907951. PubMed PMID:32284874 PubMed Central PMC7132565.
  7. Malhotra, S, Costa, C, Eixarch, H, Keller, CW, Amman, L, Martínez-Banaclocha, H et al.. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. Brain. 2020;143 (5):1414-1430. doi: 10.1093/brain/awaa084. PubMed PMID:32282893 .
  8. Calvo-Barreiro, L, Eixarch, H, Ponce-Alonso, M, Castillo, M, Lebrón-Galán, R, Mestre, L et al.. A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. Cells. 2020;9 (4):. doi: 10.3390/cells9040906. PubMed PMID:32272791 PubMed Central PMC7226819.
  9. Cappelle, S, Pareto, D, Tintoré, M, Vidal-Jordana, A, Alyafeai, R, Alberich, M et al.. A validation study of manual atrophy measures in patients with Multiple Sclerosis. Neuroradiology. 2020; :. doi: 10.1007/s00234-020-02401-3. PubMed PMID:32246177 .
  10. Gil-Varea, E, Spataro, N, Villar, LM, Tejeda-Velarde, A, Midaglia, L, Matesanz, F et al.. Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. Hum. Mutat. 2020; :. doi: 10.1002/humu.24016. PubMed PMID:32196808 .
Search PubMed

Affiliations & Other Activities

  • The Waugh Family Chair in Multiple Sclerosis Research, St. Michael’s Hospital
  • Medical Director, the BARLO MS Centre, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Division Director, Department of Neurology, University of Toronto
  • Director, Centre d’Esclerosi Múltiple de Catalunya (Cemcat)